Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and olderAndres Forero‐Torres, Christopher A. Yasenchak, Beata Holkova et al.|Blood|2015Cited by 142
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapyJonathan W. Friedberg, Christopher A. Yasenchak, Jerome H. Goldschmidt et al.|Blood|2023Cited by 42
Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma PatientsChristopher A. Yasenchak, Jonathan W. Friedberg, Rodolfo Bordoni et al.|Blood|2020Cited by 16
Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.Jonathan W. Friedberg, Christopher A. Yasenchak, Andres Forero‐Torres et al.|Journal of Clinical Oncology|2018Cited by 4
Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.Christopher A. Yasenchak, Jonathan W. Friedberg, Rodolfo Bordoni et al.|Journal of Clinical Oncology|2020Cited by 3